Home>Topics>Stocks>Idenix Pharmaceuticals

Idenix Pharmaceuticals IDIX

  1. All
  2. Commentary
  3. Headlines
    1. Achillion - An Options Strategy For A Potential Acquisition

      Headlines

      Mon, 8 Sep 2014

      By Small Pharma Analyst : A few months ago, Merck (NYSE: MRK ) surprised investors by acquiring Idenix (NASDAQ: IDIX ) for $3.85 billion, a 239% premium to its closing share price of the prior day. This was an unexpected acquisition

    2. Buying Biotech

      Headlines

      Wed, 3 Sep 2014

      of small-cap biotech companies like Idenix (NASDAQ: IDIX ) and Intermune (NASDAQ: ITMN ) . Why so many pharma deals ..... world, has agreed to pay about $3.85 billion to acquire Idenix Pharmaceuticals . Idenix is the developer of an important drug for hepatitis

    3. Veritiv Corp. For The Value Investor?

      Headlines

      Tue, 26 Aug 2014

      mostly to the performance of Idenix Pharmaceuticals Inc (NASDAQ: IDIX ) and Micron Technology (NASDAQ ..... Merck (NYSE: MRK ) acquired IDIX at $24.50 a share. Although ..... stake, Baupost sold out of IDIX August 12, 2014. Four days

    4. Arrowhead's Hep B Phase 2a Topline Data Imminent - 'Transformational' Potential

      Headlines

      Tue, 12 Aug 2014

      By R.S. Analytics : Arrowhead Research Corp. (NASDAQ: ARWR ) is a biopharmaceutical company targeting RNAi therapeutics. There are multiple compounds in Arrowhead's pipeline but the highest priority compound, and the focus of this article, is ARC-520 for hepatitis B. ARC-520 is being studied as a

    5. Enanta Pharmaceuticals Is Simply Too Cheap To Ignore

      Headlines

      Mon, 11 Aug 2014

      figures, Merck & Co. (NYSE: MRK ) decided to bolster its own hepatitis C franchise with the purchase of Idenix Pharmaceuticals (NASDAQ: IDIX ) earlier this year for $3.85 billion. While that figure pales in comparison to Gilead's purchase

    6. Merck: Should You Buy It?

      Headlines

      Mon, 11 Aug 2014

      By Balanced Investing : The players of the drug manufacturing industry constantly grapple with the reality of patent expiries. Merck (NYSE: MRK ), being one of the renowned companies in the industry, is continuously on the move to commercialize its new wave of innovative discoveries to maintain and

    7. Gilead Is Going To Make More Money In The Future

      Headlines

      Wed, 6 Aug 2014

      coincided with a timely piece at the time of concern surrounding patent litigation and Merck & Co.'s (NYSE: MRK ) buyout of Idenix (NASDAQ: IDIX ). Beyond intellectual property, Idenix has experimental hepatitis C products Complete Story »

    8. Gilead: A Growth Story

      Headlines

      Wed, 6 Aug 2014

      By Don Dion : Due to the recent release of its blockbuster hepatitis-C drug, Sovaldi, that is estimated to have nearly $5 billion in sales in the first 6-months of 2014, Gilead Sciences Inc. (NASDAQ: GILD ) is fighting a legal battle to hold off competitors who are claiming patent infringement and

    9. Idenix Pharmaceuticals misses by $0.22

      Headlines

      Thu, 31 Jul 2014

      Idenix Pharmaceuticals (NASDAQ: IDIX ): Q2 EPS of -$0.43 misses by $0.22 . Press Release Post your comment!

    10. Merck to buy Idenix for about $3.85 billion

      Headlines

      Mon, 9 Jun 2014

      June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.

    « Prev123Next »
    Content Partners